Rice University's top innovation exec leaving for new role at UVA

moving on

Paul Cherukuri, Rice’s first vice president for innovation and chief innovation officer, will leave his post next month. Photo via Rice.edu

Paul Cherukuri, Rice University's top innovation executive, responsible for some of Rice’s major innovative projects like the Rice BioTech LaunchPad and Rice Nexus, will leave the university next month to accept a position at the University of Virginia.

Cherukuri, Rice’s first vice president for innovation and chief innovation officer, will become the University of Virginia’s Donna and Richard Tadler University Professor of Entrepreneurship and the school's first chief innovation officer, according to a release from Rice. Cherukuri, who has served for more than 10 years at Rice, plans to depart his current position on Sept. 30.

Adrian Trömel, associate vice president for innovation strategy and investments at Rice, will serve as interim vice president for innovation and chief innovation officer after Cherukuri departs, and as the university starts an international search for his replacement.

“We appointed Paul to build an ambitious and high-functioning innovation operation, and he has succeeded remarkably in short order,” Rice President Reginald DesRoches said in the release. “In every area, from technology translation and startup creation to commercialization and entrepreneurship training, he has led the effort to vastly improve our structure, operations and relationships. He has contributed immensely both to our strategies and their implementation across numerous areas, and we’ll miss him greatly.”

Cherukuri is a physicist, chemist and medical technology entrepreneur, and has been a member of DesRoches’ leadership team since 2022. Cherukuri served as executive director of Rice’s Institute of Biosciences and Bioengineering from 2016 to 2022, where he helped in the development of interdisciplinary translational research partnerships with federal and corporate agencies. His work helped earn nearly $37 million in funding for accelerating the development of new technologies into commercial products. In the energy transition field, Cherukuri led a $12.5 million partnership with Woodside Energy to transform greenhouse gases into advanced nanomaterials for next-generation batteries and transistors.

Initiatives the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion; were all launched under Cherukuri’s leadership. With his work at the Ion, Cherukuri also led the announcement of a partnership with North America’s largest climate tech incubator, Greentown Labs.

“I am proud of the relentless innovative spirit we have built for Rice in Houston and around the world,” Cherukuri said in the release. “I look forward to bringing new energy and vision to UVA’s efforts in this critical space for our country, its success and future.”

From Your Site Articles
Four Rice University lab-stage innovations are receiving fresh funding to get them closer to commercialization. Photo courtesy of Rice University

Rice names inaugural recipients of new grant program that's doling out $360,000

Four Houston research projects are splitting hundreds of thousands of dollars in grant funding from Rice University.

After announcing the One Small Step Grant program in September to support Rice-developed, lab-stage innovations, the university has named its inaugural recipients. After receiving nearly 30 applicants, four research projects were selected to share $360,000 in grant funding.

“Being able to fund near-commercial projects represents a leap forward in our mission of supporting the cutting-edge work of our faculty and students and helping bring those to market,” Adrian Trömel, assistant vice president for strategy and investments, says in a news release. “Feedback from industry and investors show that they’re excited on how the One Small Step grants help derisk these technologies, getting them ready to launch. Watch this space for the next generation of leading deeptech companies.”

The selected projects include:

  • PerisBio, developed by Samira Aglhara Fotovat and Samantha Fleury from Rice Professor Omid Veiseh's Lab, focuses on novel, hydrogel-encapsulated engineered "cell factories" for the minimally invasive treatment of endometriosis. The project received a $100,000 award.
  • Solidec, founded by Ryan Duchanois and Yang Xia from Rice Professor Haotian Wang's Lab, is a room temperature, solid-state direct air capture technology. The project received a $100,000 award.
  • HornetX, led by Rice Professor Aditya Mohite's Lab, aims to produce highly stable green hydrogen using a perovskite-based photoelectrochemical cell with leading efficiency. The project received a $80,000 award.
  • Coflux, developed by Jeremy Daum and Alec Ajnsztajn from the labs of Rice Professors Rafael Verduzco and Pulickel Ajayan, focuses on covalent organic framework-based photocatalysts for instream remediation of PFAS (per- and polyfluoroalkyl substances) from water. The project received a $80,000 award.

The Office of Innovation created an investment advisory committee — made up of entrepreneurs, investors and corporate executives across industries — to select these recipients. The grant program was funded by the Office of Innovation, with support from Breakthrough Energy Fellows for climate and energy projects

“The inaugural winners of the One Small Step Grant represent the innovative spirit and dedication to excellence that defines our students and faculty," Rice Chief Innovation Officer Paul Cherukuri says. "We are proud to support these groundbreaking projects on their journey from lab to market."

Former University of St. Thomas business school dean, Beena George, is taking on a new role at the university: Chief innovation officer. Courtesy of UST

Houston educator plans to lead her university into the future with her new role

Featured innovator

High school graduation numbers are decreasing, and, by 2025, far fewer college freshmen will be starting school. Some project as high as a 15 percent drop, says Beena George, inaugural chief innovation officer of Houston's St. Thomas University.

UST is looking forward to and anticipating changes and challenges within higher education like this, and one of the steps the university has been to create George's position.

"My role is to ferment that culture of innovation," George says. "Not just sit here and think of ideas."

As the school gets ready to welcome students back onto its Montrose campus, the former business dean gets ready to serve in her new role for the first semester. She spoke with InnovationMap about her career, goals, and the role UST plays within the Houston innovation ecosystem.

InnovationMap: What have you learned throughout your career that has prepared you for the role?

Beena George: I've always been interested in solving problems. If I saw something that was an opportunity, and we didn't take advantage of it, I'll keep thinking about it. I've been thinking about what makes me enjoy this role and stage in my career, and I think it's because most roles tend to be mostly operational, but this is thinking of new things and doing things differently and checking your own assumptions. That is what really engages me in my role. My career has given me different opportunities to use this, but not so much as now. When teaching, you have that opportunity every day — engaging students differently. Then as dean, it was about looking at new opportunities and programs for the business school, like our Master of Clinical Translation Management program.

IM: How did this clinical translation program come about?

BG: The idea of clinical translation is essentially to move a discovery from the lab to the patient's bedside — it's the commercialization of life sciences. The program trains students to shepherd a discovery from the lab to the commercial setting so that it's available to patients.It's a combination of business, life sciences, regulatory affairs. It's a one-year online program with some residency periods. It's the only of its kind in Houston and is one of less than 10 in the United States and, to my knowledge, the only of its kind in a business school.

IM: What does innovation mean to the University of St. Thomas and this inaugural position?

BG: I think innovation isn't entirely new on college campuses, but now is a time when higher education is in flux. There has been a lot of changes in the industry and in society in general that's requiring higher education institutions to react in a different way. Some of the things that we've always been doing — creating new programs, moving online, new campuses — now it's even more important to bring that to prominence and figure out how it fits with your university. Things have changed, so the rate at which you're innovating has to increase.

IM: What’s on your to-do list for this first year and within five years?

BG: Since this is a new role, my first goal for the next two to three months is the process of discovery — internally and externally. One of the cool things that's happening in Houston is all these partnerships and collaborations. That's what I'm trying to do — learn about the groups here and outside and make these connections. The other part of it is bringing information in from the outside. There are so many different ways of doing things. For instance, in higher education, it's been historically tied to credit hours. We know now there are many different ways to look at education. That's the kind of conversation I look to get started.

IM: You mention collaboration, and I think that’s key when it comes to higher education institutions within the innovation ecosystem, but how do you see that teamwork affecting the city as a whole?

BG: So I have been so glad to see that, because I've always believed that there has to be some competition — it ensures that everyone performs at their best. But there are some industries where you have to go beyond competition to the next level and manage competition and collaboration at the same time. We have two networks — Texas Medical Center and the academic partnership created by The Ion — and talk about what's happening on your campuses and how we can work together in Houston. There's also the 60x30 Texas, which has different advisory councils that offers that same conversation of collaboration to work together to meet our goals. Those types of conversations are important and having those types of venues to do that can have only a positive effect on Houston.

IM: How is UST finding new ways to prepare its students for the workforce?

BG: One thing that has gained a lot of attention here on campus is providing students with more experiential learning opportunities — more internships and apprenticeships and bringing the industry into the classroom. Carlos Monroy, a professor at UST, and his student worked on a project for the city. This is something that allows us to remain connected to the industry and it gives our faculty the idea of what the Industry needs and they can focus on that in the classroom.

IM: UST recently announced a major “renewal” plan. How is this going to affect innovation efforts on campus?

BG: I think the whole process is about innovation. What we have is an opportunity to recreate ourselves for the next millennium and create a sustainable operating model that will continue to provide for our students. I think it will affect everything.


------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."

7 Houston neighbors named to U.S. News' best places to live in 2026

Living Well

Several Houston suburbs have been crowned the best places to live in the U.S. for 2026, according to U.S. News & World Report. Sugar Land is the highest-ranked city in the Houston metro, and it ranks as the 10th best place to live in the country.

The annual list of Best Places to Live in the U.S. is designed to help readers make the most informed decisions when choosing where to settle down, using data from sources such as the U.S. Census Bureau, Department of Commerce, the Federal Reserve and the Bureau for Economic Analysis, as well as state and local sources.

For the 2026-2027 rankings, U.S. News featured 250 U.S. cities and ranked them across four livability indexes — quality of life, value, desirability, and job market — weighted by importance based on survey results of approximately 500 Americans. The rankings were also broken down state-by-state, as well as the best big, medium, and small cities overall.

Sugar Land is the No. 4 best places to live in Texas, and it soared into the No. 10 spot overall in the nation after ranking 16th last year. Sugar Land also ranks as the fourth-best mid-sized city to live in America for 2026-2027.

According to U.S. News, Sugar Land's median household income is far higher than the national average. Residents make $140,511 per year, while the average American household income is only $83,181.

Additionally, the $431,815 median home value in Sugar Land is also far greater than the $359,870 national average.

After ranking in the top 10 in the 2025 report, League City and Pearland now both rank outside the national top 10 for 2026. League City slipped from No. 6 to No. 13 this year, while Pearland dropped from No. 3 nationwide to No. 16.

These three Houston suburbs also boast highly desirable job markets for potential newcomers or current residents that want to start or change their career.

Houston proper, however, remains outside of the top 250 and is the 327th best place to live in the U.S., and it's the 60th best place to live in Texas.

Other cities in the greater Houston area that ranked among the top 100 include:

  • No. 28 – The Woodlands
  • No. 38 – Katy
  • No. 61 – Missouri City
  • No. 82 – Spring

The Lone Star State had a "strong showing" in the overall top 10 thanks to its "high affordability scores," a release said. Besides Sugar Land, three more popular Texas suburbs made the cut: Leander (No. 8) outside Austin and Dallas-Fort Worth suburbs Flower Mound (No. 3) and Frisco (No. 9).

"As prices of everyday goods continue to rise, consumers are considering affordability as a top priority when choosing a place to live," said U.S. News consumer lending analyst Erika Giovanetti. "While U.S. News’ consumer survey indicated that quality of life and affordability were close in importance, cost-of-living concerns resulted in many Americans putting what they can afford above their aspirations."

---

This article originally appeared on CultureMap.com.

View All Listings